Abstract
A recombinant adeno-associated viral (rAAV) vector system has frequently been used for gene transfer to rat substantia nigra (SN), and we have previously demonstrated that this technique (rAAV- α-synuclein) induced α-synucleinopathy, which closely resembles pathogenic changes in Parkinson's disease (PD). In the present study, the neuroprotective effect of parkin was examined by co-infection of rAAV-parkin with rAAV- α-synuclein into dopaminergic neurons in SN. At 13 weeks post-rAAV infection, α-synuclein overexpression induced dopaminergic neuron loss, while co-expression of parkin mitigated the α-synuclein toxicity. Moreover, α-synuclein-induced dopaminergic neuron loss consequently resulted in motor dysfunction, which was also mitigated by parkin. Taken together, our results indicate that parkin gene therapy is effective against α-synucleinopathy, suggesting its potential suitability for patients with PD.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
